← Leaderboards
John A Martignetti
Mount Sinai School Of Medicine Of Nyu
$4,360,123
Attributed
$5,436,173
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $924.3K · FY2005–23$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$5,436,173 · 6
By mechanism
R01$4,711,453 · 3
R41$399,972 · 1
K08$255,960 · 1
M01$68,788 · 1
Top collaborators
- Aneta Joanna Mieszawska10 shared
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceMouse ModelTumorMolecularMalignant NeoplasmsDiagnosticDiagnosisTumor GrowthIn VivoCoupledCancer CellCell ProliferationHistologyCellsBaseIn VitroBiologicalUnited StatesWomanMalignant Female Reproductive System NeoplasmMalignant Neoplasm Of OvaryEnsureBioluminescence ImagingAdverse Effects
Grant awards (24)
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$323,970
R01 · FY2023 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$323,970
R01 · FY2022 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$118,979
R01 · FY2022 · CA
Development of a biomarker panel for screening and early detection of gynecological cancers$399,972
R41 · FY2021 · CA · contact PI
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$330,582
R01 · FY2021 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$121,408
R01 · FY2021 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$72,341
R01 · FY2021 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$330,582
R01 · FY2020 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$121,408
R01 · FY2020 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$66,737
R01 · FY2020 · CA
Anti-vascular and cytotoxic nanoparticle formulations for ovarian cancer therapy$342,124
R01 · FY2019 · CA
Role of the tumor suppressor KLF6 in prostate cancer$312,340
R01 · FY2011 · CA · contact PI
Role of the tumor suppressor KLF6 in prostate cancer$315,400
R01 · FY2010 · CA · contact PI
Role of the tumor suppressor KLF6 in prostate cancer$315,400
R01 · FY2009 · CA · contact PI
Role of the tumor suppressor KLF6 in prostate cancer$315,400
R01 · FY2008 · CA · contact PI
Association of 7q22..1 gene VGF with obesity & leanness$236,252
R01 · FY2008 · DK · contact PI
Role of the tumor suppressor KLF6 in prostate cancer$328,605
R01 · FY2007 · CA · contact PI
Association of 7q22..1 gene VGF with obesity & leanness$241,075
R01 · FY2007 · DK · contact PI
Association of 7q22..1 gene VGF with obesity & leanness$248,275
R01 · FY2006 · DK · contact PI
Association of 7q22..1 gene VGF with obesity &leanness$246,605
R01 · FY2005 · DK
GENETIC DISSECTION OF A BONE DYSPLASIA/CANCER SYNDROME$85,320
K08 · FY2002 · HD
GENETIC DISSECTION OF A BONE DYSPLASIA/CANCER SYNDROME$85,320
K08 · FY2001 · HD
GENETIC DISSECTION OF A BONE DYSPLASIA/CANCER SYNDROME$85,320
K08 · FY2000 · HD
POSITIONAL CLONING OF THE GENE FOR HEREDITARY BONE DYSPLASIA$68,788
M01 · FY2000 · RR